Global Depression Drugs Market 2014-2018


◆タイトル:Global Depression Drugs Market 2014-2018
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:pdf / 英語
Single User LicenseUSD2,500 ⇒換算¥265,000見積依頼/購入/質問フォーム
Five User License USD2,800 ⇒換算¥296,800見積依頼/購入/質問フォーム
Enterprise License USD3,500 ⇒換算¥371,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



TechNavio’s analysts forecast the Global Depression Drugs market to grow at a CAGR of 2.49 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in the number of patients suffering from depression. The Global Depression Drugs market has also been witnessing the growing awareness of depression drugs. However, the generic erosion of key blockbuster drugs could pose a challenge to the growth of this market.
TechNavio’s report, the Global Depression Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Depression Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space are GlaxoSmithKline plc, Eli Lilly & Co., Pfizer Inc., and Forest Laboratories Inc.
Other vendors mentioned in the report are Astra Zeneca plc, Bristol Myers Squibb Co., Mallinckrodt Pharmaceuticals Inc., Sanofi Aventis S.A., and Takeda Pharmaceutical Company Ltd.
Key questions answered in this report:
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Product Types
08. Market Segmentation by Category
09. Geographical Segmentation
10. Buying Criteria
11. Rate of Incidence and Prevalence
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 GlaxoSmithKline plc
18.1.1 Business Overview
18.1.2 Business Segmentation
18.1.3 Key Information
18.1.4 SWOT Analysis
18.2 Eli Lilly & Co.
18.2.1 Business Overview
18.2.2 Key Information
18.2.3 SWOT Analysis
18.3 Pfizer Inc.
18.3.1 Business Overview
18.3.2 Business Segmentation
18.3.3 Key Information
18.3.4 SWOT Analysis
18.4 Forest Laboratories Inc.
18.4.1 Business Overview
18.4.2 Key Information
18.4.3 SWOT Analysis
19. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Depression Drugs Market 2013-2018 (US$ billion)
Exhibit 3: Global Depression Drugs Market Segmentation by Product Types
Exhibit 4: Global Depression Drugs Market Segmentation by Category
Exhibit 5: Global Depression Drugs Market by Geographical Segmentation 2013
Exhibit 6: Global Depression Drugs Market by Vendor Segmentation 2013
Exhibit 7: Business Segmentation of GlaxoSmithKline plc
Exhibit 8: Business Segmentation of Pfizer Inc.


GlaxoSmithKline plc, Eli Lilly & Co., Pfizer Inc., and Forest Laboratories Inc.



★調査レポート[世界の抗うつ薬市場動向(2014~2018)] (Global Depression Drugs Market 2014-2018 / IRTNTR3162)販売に関する免責事項
[世界の抗うつ薬市場動向(2014~2018)] (Global Depression Drugs Market 2014-2018 / IRTNTR3162)についてEメールでお問い合わせ